San Diego saw seven IPOs in 2018, largely dominated by life sciences companies.
San Diego-based Neurocrine’s drug for Tourette syndrome failed to meet its primary goal in a mid-stage clinical trial, the company reported Dec. 12.
The San Diego Business Journal frequently chronicles local funding rounds and the big dreams that accompany them. But what about the largest venture capital sources locally?
Recently proposed legislation would further push back a 2.3 percent excise tax on medical device makers, San Diego’s ResMed, NuVasive and Ra Medical Systems among them.
Pharmaceutical behemoth Pfizer is set to close a South San Francisco site and relocate 100 jobs to its research and development campus in La Jolla.
Human Longevity Inc.’s latest valuation: $310 million, down more than 80 percent from early 2017, according to the Wall Street Journal.
Oxeia Leading the Pack on Potential Concussion Treatments
Precision health factors in a person’s genes, medical history, environment and more for diagnosis and treatment.
LunaDNA’s first-of-its-kind platform giving shares for contributing DNA data got approval earlier this week from the U.S. Securities and Exchange Commission.
Biogen exercised a licensing option and will pay Carlsbad’s Ionis Pharmaceuticals $35 million for a drug candidate aimed at amyotrophic lateral sclerosis, or ALS.
ViaCyte recently hauled in an $80 million Series D round to advance therapies that the company called a potential “functional cure” for Type 1 diabetes patients.
San Diego-based Viracta Therapeutics intends to bring a cancer therapy candidate to China through a recently inked partnership with Chinese drug company Salubris
LEGAL: AMN Loses Bid to Limit Ex-Recruiters’ Actions
A recent ruling involving competing health care staffing firms headquartered in San Diego makes it tougher for employers to restrict past employees from soliciting former clients.
Neurelis has acquired Aegis Therapeutics, bringing together two San Diego companies.